HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,780 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Follow-Up Questions
Who is the CEO of HUTCHMED (China) Ltd?
Dr. Weiguo Su is the Chief Executive Officer of HUTCHMED (China) Ltd, joining the firm since 2017.
What is the price performance of HMDCF stock?
The current price of HMDCF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for HUTCHMED (China) Ltd?
HUTCHMED (China) Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is HUTCHMED (China) Ltd market cap?
HUTCHMED (China) Ltd's current market cap is $0
Is HUTCHMED (China) Ltd a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for HUTCHMED (China) Ltd, including 9 strong buy, 15 buy, 3 hold, 0 sell, and 9 strong sell
